Abstract:
A docetaxel nano-polymer micelle lyophilized preparation is disclosed including methoxypolyethylene glycol-polylactic acid block copolymer carrier material and docetaxel, the docetaxel being is encapsulated in the carrier material. A mass ratio of the docetaxel to the carrier material is 0.01-0.15. The methoxypolyethylene glycol-polylactic acid block copolymer is formed by ring opening polymerization of D,L-lactide and methoxypolyethylene glycol. A mass ratio of the methoxypolyethylene glycol to the D,L-lactide is 1:0.55-0.65 or 1:0.73-0.89 or 1:0.91-0.99. The mass ratio of the docetaxel to the carrier is further optimized by adjusting a mass ratio of polyester to polyether in the methoxypolyethylene glycol polylactide block copolymer. The encapsulation efficiency of a docetaxel micelle prepared by the block copolymer after being re-dissolved by water can be greater than 90% at 12 hours.

Description:
TECHNICAL FIELD 
       [0001]    The present invention belongs to the technical field of drugs, and more particularly, relates to a docetaxel nano-polymer micelle lyophilized preparation and a preparation method thereof. 
       BACKGROUND 
       [0002]    Docetaxel (docetaxel, DTX) is a taxol antineoplastic drug with a molecular formula of C43H53NO14 and a molecular weight of 807.88, which may be combined with a free tubulin to promote the tubulin to be assembled into a stable microtubule, and meanwhile suppress the depolymerization of the tubulin, and cause the generation of a microtubule bundle losing normal functions and fixation of the microtubule, thus suppressing cell mitosis and playing an antineoplastic role. Docetaxel is clinically applied to breast cancer, non-small cell lung cancer, pancreatic cancer, soft tissue sarcoma, head and neck cancer, stomach cancer, ovarian cancer and prostatic cancer or the like, and has notable curative effects no matter it is applied alone or in combination. 
         [0003]    However, the docetaxel has such defects like poor water solubility, short half life period and high toxicity at the same time, which limit its clinic applications. At present, docetaxel injections commercially available at home and abroad are prepared by dissolving docetaxel in Tween-80, and need to be diluted using a specialized solvent for injection strictly during clinic application. Its operation requirements are strict and its use method is tedious. Moreover, a large amount of Tween contained in the preparation is easy to cause such adverse reactions as hemolysis and allergy or the like, which needs to take such drugs like dexamethasone in advance for control, is inconvenient for clinic medication, and has low medication safety. So far, this problem has not been preferably solved yet. 
         [0004]    A nano-polymer micelle is a drug carrier system developed in recent years direct to indissolvable drugs, which has a core-shell structure, wherein the core is a hydrophobic part, and the shell is a hydrophilic part. The polymer micelle may encapsulate the indissolvable drugs into the core part to solubilize the indissolvable drugs. Compared with a normal solubilizer and latent solvent, the polymer micelle drug carrier system has higher security since it selects biodegradable material as raw materials. Therefore, it has a better application prospect while being served as an encapsulating-carrying accessory for the indissolvable drugs. In multiple technologies, a micelle prepared by the methoxypolyethylene glycol-polylactic acid block copolymer block polymer and the docetaxel is applied to try to solve the difficulty; for example, CN201110105540 discloses a micelle prepared by a methoxypolyethylene glycol-polylactic acid block copolymer and docetaxel, which solves the solubilization problem of docetaxel. 
         [0005]    However, the present micelle prepared by the methoxypolyethylene glycol-polylactic acid block copolymer and the docetaxel has poorer stability after being dispersed by water, and the drugs are leaked in a very short time, so that it cannot be further popularized and truly applied during clinic application since its physical stability is not high. In order to solve the problem, CN201010114289 discloses a technology which improves the stability of a micelle after re-dissolving through a method of adding amino acid in a polymer micelle, but the added substances have higher requirements on industrialized production, and a stabilizer added increases the technical complexity of the preparation, and meanwhile, the added amino acid plays a role of degrading the main drugs, which is not suitable for large-scale production. 
       SUMMARY 
     Object of the Invention 
       [0006]    In order to solve the technical problems existed in the prior art, the present invention provides a docetaxel nano-polymer micelle lyophilized preparation, wherein the time for the encapsulation efficiency of the docetaxel nano-polymer micelle after being re-dissolved by water greater than 90% can reach more than 12 h. 
         [0007]    Another technical problem to be solved by the present invention is to provide a preparation method of the foregoing docetaxel nano-polymer micelle lyophilized preparation and applications thereof. 
       Technical Content 
       [0008]    To fulfill the foregoing technical object, the present invention adopts the following technical solution. 
         [0009]    A docetaxel nano-polymer micelle lyophilized preparation includes methoxypolyethylene glycol-polylactic acid block copolymer carrier material and docetaxel, and the docetaxel is encapsulated in the carrier material, wherein a mass ratio of the docetaxel to the carrier material is 0.01˜0.15; the methoxypolyethylene glycol-polylactic acid block copolymer is a block copolymer formed by ring opening polymerization of D,L-lactide and methoxypolyethylene glycol, and a mass ratio of the methoxypolyethylene glycol to the D,L-lactide is 1:0.55˜0.65 or 1:0.73˜0.89 or 1:0.91˜0.99. the mass ratio of the methoxypolyethylene glycol to the D,L-lactide has a great influence on the encapsulation efficiency of the micelle formed by the synthesized block copolymer and re-dissolved by water; therefore, the dosage of the methoxypolyethylene glycol and the D,L-lactide needs to be controlled strictly. 
         [0010]    Preferably, a mass ratio of the docetaxel to the carrier material is 0.02˜0.09. 
         [0011]    The molecular weight of the methoxypolyethylene glycol is 1000˜20000, and preferably, the molecular weight of the methoxypolyethylene glycol is 2000 or 5000. 
         [0012]    The present invention also provides a preparation method of the foregoing docetaxel nano-polymer micelle lyophilized preparation, including the following steps of: 
         [0013]    (1) synthesizing a methoxypolyethylene glycol-polylactic acid block copolymer carrier material; 
         [0014]    (2) preparing a drug-carrying micelle aqueous solution using a filming-rehydration method: dissolving docetaxel with a formula ratio and the methoxypolyethylene glycol-polylactic acid block copolymer carrier material prepared in step (1) in an organic solvent, mixing and shaking evenly, performing rotary evaporation to remove the organic solvent, obtaining a gel-like drug film of the drug and the carrier material, then adding water in the drug film to dissolve and disperse the drug film, thus preparing a micelle solution; and wherein the organic solvent is any one or more of acetonitrile, methanol, acetone, methylene chloride, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, acetone, short chain fatty alcohol and ethyl acetate, and the dosage of the organic solvent is that 0.5˜2 ml of the organic solvent is added in 1 g of the methoxypolyethylene glycol polylactic acid block copolymer carrier material, and preferably, the organic solvent is any one of methylene chloride, methanol, acetone or ethyl acetate; and 
         [0015]    (3) subjecting the micelle solution prepared in step (2) to filtration sterilization and lyophilizing, thus obtaining the docetaxel nano-polymer micelle lyophilized preparation. 
         [0016]    To be specific, the methoxypolyethylene glycol-polylactic acid block copolymer carrier material is prepared through a method as follows: weighing D,L-lactide and methoxypolyethylene glycol with a formula ratio for standby application, subjecting methoxypolyethylene glycol with a formula ratio to vacuum drying for 2˜8 h under 60˜130° C. in a reactor, performing nitrogen displacement, then adding the D,L-lactide with a formula ratio, adding catalyst stannous octoate, the mass of the stannous octoate occupying 0.05 wt %˜0.5 wt % of the total mass of the D,L-lactide and the methoxypolyethylene glycol, then performing evacuation, maintaining a reaction temperature at 60˜130° C., performing nitrogen displacement for three times after the D,L-lactide is completely fused, then performing evacuation, ensuring that the reactor has a negative pressure and is sealed or protected by nitrogen, then raising temperature 125˜150° C., reacting for 6-20 h, thus obtaining a pale yellow clear viscous liquid after the reaction is completed; adding an organic solvent in the pale yellow clear viscous liquid for dissolution, stirring for 30˜50 min, then continuously adding anhydrous ice diethyl ether and stirring for 20˜40 min, standing for 12˜24 h under 0˜5° C., then performing vacuum drying after suction filtration, thus obtaining the methoxypolyethylene glycol-polylactic acid block copolymer. Wherein, the organic solvent is any one or more of acetonitrile, methanol, acetone, methylene chloride, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, acetone, short chain fatty alcohol and ethyl acetate, and the dosage of the organic solvent is that 0.2˜1 ml of the organic solvent is added in 1 g of the pale yellow clear viscous liquid, and preferably, the organic solvent is any one of acetonitrile, methanol, acetone or ethyl acetate. Wherein, the dosage of the anhydrous ice diethyl ether is that 5˜10 ml of anhydrous ice diethyl ether is added in 1 g of the pale yellow clear viscous liquid. 
         [0017]    Preferably, the dosage of water added in the drug film is that 2˜40 ml of water is added in 1 g of the methoxypolyethylene glycol polylactic acid block copolymer carrier material, and more preferably, 5˜25 ml of water is added in 1 g of the methoxypolyethylene glycol polylactic acid block copolymer carrier material. 
         [0018]    Preferably, in step (2), the conditions for removing the organic solvent via rotary evaporation are that: a rotation velocity is 10˜150 rpm, a temperature is 20˜80° C., and a time is 1˜4 h. 
       Advantageous Effects 
       [0019]    According to the present invention, the block copolymer prepared by methoxypolyethylene glycol and D,L-lactide with a proper mass ratio is employed as the carrier material and meanwhile a proper proportion between the drug and the carrier material is selected, such that the time for the encapsulation efficiency of the docetaxel nano-polymer micelle lyophilized preparation prepared after being re-dissolved by water greater than 90% can reach more than 12 h, the effect of which is far better than that of a common lyophilized preparation, and complies with the actual situations of clinic drug application, thus satisfying clinic requirements. Through preferred molecular weight and drug-carrying amount of the micelle, the docetaxel is preferably encapsulated by the carrier, thus improving the stability. 
     
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         [0020]      FIG. 1  is a CDCl 3    1 HNMR profile of a methoxypolyethylene glycol polylactic acid block copolymer; 
           [0021]      FIG. 2  is a GPC profile of the methoxypolyethylene glycol polylactic acid block copolymer; 
           [0022]      FIG. 3  is a CDCl 3    1 HNMR profile of a docetaxel polymer micelle lyophilized preparation; 
           [0023]      FIG. 4  is a D 2 O  1 HNMR profile of the docetaxel polymer micelle lyophilized preparation; 
           [0024]      FIG. 5  is a CDCl 3    1 HNNMR profile of the methoxypolyethylene glycol polylactic acid block copolymer; 
           [0025]      FIG. 6  is an infrared spectrum of the methoxypolyethylene glycol polylactic acid block copolymer; 
           [0026]      FIG. 7  is an infrared spectrum of docetaxel; 
           [0027]      FIG. 8  is an infrared profile of a docetaxel polymer micelle; 
           [0028]      FIG. 9  is a thermal-scanning profile of docetaxel; 
           [0029]      FIG. 10  is a thermal-scanning profile of the methoxypolyethylene glycol polylactic acid block copolymer; and 
           [0030]      FIG. 11  is a thermal-scanning profile of the docetaxel polymer micelle. 
       
    
    
     DETAILED DESCRIPTION 
       [0031]    The foregoing contents of the invention will be further explained in details by means of experimental examples hereinafter, but it should not be understood that the scope of the foregoing subject of the invention is only limited to the following examples, and any technology implemented based on the foregoing contents of the invention shall all fall within the scope of the invention. 
       Embodiment 1: Preparation of Methoxypolyethylene Glycol-Polylactic Acid Block Copolymer 
       [0032]    (1) 51.07 g of D,L-lactide and 50.57 g of methoxypolyethylene glycol 2000 were weighed for standby application, the methoxypolyethylene glycol 2000 was subjected to vacuum drying for 7 h under 100□, nitrogen displacement was performed, D,L-lactide was added, and 0.2 g of catalyst stannous octoate was added, evacuation was performed to a vacuum degree of 0.096 Mpa, a reaction temperature was maintained at 100° C., nitrogen displacement was performed for three times after the D,L-lactide was completely fused, evacuation was performed, the reactor was ensured to have a negative pressure and was sealed, then the temperature was raised to 140° C., and reaction was performed for 12 h, thus obtaining a pale yellow clear viscous liquid after the reaction was completed. 
         [0033]    (2) 25 ml of methylene chloride was added into the pale yellow clear viscous liquid obtained in step (1), and stirred for 30 min; then 510 ml of anhydrous ice diethyl ether was added, and stirred for 30 min; then standing was performed for 12 h under 0° C., vacuum drying was performed after suction filtration, thus obtaining the methoxypolyethylene glycol-polylactic acid block copolymer; refining was performed for three times according to the foregoing operation process to obtain the methoxypolyethylene glycol-polylactic acid block copolymer, wherein the total yield was about 75%. The obtained polymer was characterized using nuclear magnetic resonance and gel chromatography, wherein the results were as shown in  FIG. 1  and  FIG. 2 .  FIG. 1  is characterization of various hydrogens in the methoxypolyethylene glycol-polylactic acid block copolymer, proving that the methoxypolyethylene glycol-polylactic acid block copolymer is synthesized. The detection results of  FIG. 2  are as follows: Mp: 6330; Mn: 5887; Mw: 6374; Mz: 6873; M z+1 : 7393; Mv: 6301; and PDI: 1.08272. 
       Embodiment 2: Preparation of Methoxypolyethylene Glycol-Polylactic Acid Block Copolymer 
       [0034]    (1) 48.77 g of D,L-lactide and 51.27 g of methoxypolyethylene glycol 2000 were weighed for standby application, the methoxypolyethylene glycol 2000 was subjected to vacuum drying for 5 h under 120° C., nitrogen displacement was performed, D,L-lactide was added, and then 0.048 g of catalyst stannous octoate was added, evacuation was performed to a vacuum degree of 0.095 Mpa, a reaction temperature was maintained at 120° C., nitrogen displacement was performed for three times after the D,L-lactide was completely fused, evacuation was performed, the reactor was ensured to have a negative pressure and protected by nitrogen, then the temperature was raised to 140° C., and reaction was performed for 14 h, thus obtaining a pale yellow clear liquid after the reaction was completed. 
         [0035]    (2) 29 ml of methylene chloride was added into the foregoing pale yellow clear liquid for dissolution, and was stirred and dissolved; then 586 ml of anhydrous ice ethyl ether was added, and stirred for 30 min; standing was performed for 12 h under 5° C., then vacuum drying was performed after suction filtration. Refining was performed for three times according to the foregoing operation process to obtain the methoxypolyethylene glycol-polylactic acid block copolymer, wherein the total yield was about 85%. 
       Embodiment 3: Preparation of Methoxypolyethylene Glycol-Polylactic Acid Block Copolymer 
       [0036]    (1) 47.53 g of D,L-lactide and 52.17 g of methoxypolyethylene glycol 2000 were weighed for standby application, the methoxypolyethylene glycol 2000 was subjected to vacuum drying for 7h under 130° C., nitrogen displacement was performed, 0.3 g of catalyst stannous octoate was added and then D,L-lactide was added, evacuation was performed to a vacuum degree of 0.093 Mpa, a reaction temperature was maintained at 130° C., nitrogen displacement was performed for three times after the D,L-lactide was completely fused, evacuation was performed, the reactor was ensured to have a negative pressure and was sealed, then the temperature was raised to 150° C., and reaction was performed for 6 h, thus obtaining a pale yellow clear liquid after the reaction was completed. 
         [0037]    (2) 45 ml of methylene chloride was added into the foregoing pale yellow clear liquid in step (1), and was stirred and dissolved; then 550 ml of anhydrous ice ethyl ether was added, and stirred for 30 min; standing was performed for 12 h under 0° C., then vacuum drying was performed after suction filtration. Refining was performed for three times according to the foregoing operation process to obtain the methoxypolyethylene glycol-polylactic acid block copolymer, wherein the total yield was about 80%. 
       Embodiment 4: Preparation of Methoxypolyethylene Glycol-Polylactic Acid Block Copolymer 
       [0038]    (1) 47.11 g of D,L-lactide and 52.85 g of methoxypolyethylene glycol 2000 were weighed for standby application, the methoxypolyethylene glycol 2000 was subjected to vacuum drying for 4 h under 120□, D,L-lactide was added, and then 0.4 g of catalyst stannous octoate was added, evacuation was performed to a vacuum degree of 0.093 Mpa, a reaction temperature was maintained at 120° C., after the D,L-lactide was completely fused, evacuation was performed, the reactor was ensured to have a negative pressure and was sealed, then the temperature was raised to 130° C., and reaction was performed for 18 h, thus obtaining a pale yellow clear viscous liquid after the reaction was completed. 
         [0039]    (2) 40 ml of methylene chloride was added into the foregoing pale yellow clear viscous liquid obtained in step (1) for dissolution, and was stirred for 30 min; then 500 ml of anhydrous ice diethyl ether was added, and stirred for 30 min; standing was performed for 12 h under 0° C., vacuum drying was performed after suction filtration, and refining was performed for three times according to the foregoing operation process to obtain the methoxypolyethylene glycol-polylactic acid block copolymer, wherein the total yield was about 80%. 
       Embodiment 5: Preparation of Methoxypolyethylene Glycol-Polylactic Acid Bock Copolymer 
       [0040]    (1) 45.91 g of D,L-lactide and 54.06 g of methoxypolyethylene glycol 2000 were weighed for standby application, the methoxypolyethylene glycol 2000 was subjected to vacuum drying for 3 h under 120° C., nitrogen displacement was performed, then D,L-lactide was added, and 0.25 g of catalyst stannous octoate was added, evacuation was performed, a reaction temperature was maintained at 120° C., after the D,L-lactide was completely fused, nitrogen displacement was performed for three times, the reactor was ensured to have a negative pressure and was sealed, then the temperature was raised to 140° C., and reaction was performed for 12 h, thus obtaining a pale yellow clear viscous liquid after the reaction was completed. 
         [0041]    (2) 50 ml of methylene chloride was added into the pale yellow clear viscous liquid obtained in step (1), and stirred for 30 min; then 500 ml of anhydrous ice diethyl ether was added, and stirred for 30 min; standing was performed for 12 h under 0° C., vacuum drying was performed after suction filtration, and refining was performed for three times according to the foregoing operation process to obtain the methoxypolyethylene glycol-polylactic acid block copolymer, wherein the total yield was about 75%. 
       Embodiment 6: Preparation of Methoxypolyethylene Glycol-Polylactic Acid Block Copolymer 
       [0042]    (1) 44.45 g of D,L-lactide and 55.68 g of methoxypolyethylene glycol 2000 were weighed for standby application, the methoxypolyethylene glycol 2000 was subjected to vacuum drying for 5 h under 110° C., nitrogen displacement was performed, then D,L-lactide was added, and 0.36 g of catalyst stannous octoate was added, evacuation was performed to a vacuum degree of 0.09 Mpa, a reaction temperature was maintained at 110° C., after the D,L-lactide was completely fused, evacuation was performed, the reactor was ensured to have a negative pressure and was sealed, the temperature was controlled to be raised to 140° C., and reaction was performed for 14 h, thus obtaining a pale yellow clear viscous liquid after the reaction was completed. 
         [0043]    (2) 60 ml of methylene chloride was added into the pale yellow clear viscous liquid obtained in step (1), and stirred for 30 min; then 660 ml of anhydrous ice diethyl ether was added, and stirred for 30 min; standing was performed for 12 h under 0° C., vacuum drying was performed after suction filtration, and refining was performed for three times according to the foregoing operation process to obtain the methoxypolyethylene glycol-polylactic acid block copolymer, wherein the total yield was about 80%. 
       Embodiment 7: Preparation of Methoxypolyethylene Glycol-Polylactic Acid Block Copolymer 
       [0044]    (1) 39.51 g of D,L-lactide and 61.77 g of methoxypolyethylene glycol 2000 were weighed for standby application, the methoxypolyethylene glycol 2000 was subjected to vacuum drying for 6 h under 100° C., nitrogen displacement was performed, then D,L-lactide was added, and 0.08 g of catalyst stannous octoate was added, evacuation was performed to a vacuum degree of 0.098 Mpa, a reaction temperature was maintained at 100° C., after the D,L-lactide was completely fused, evacuation was performed, the reactor was ensured to have a negative pressure and was sealed, the temperature was controlled to be raised to 140° C., and reaction was performed for 12 h, thus obtaining a pale yellow clear viscous liquid after the reaction was completed. 
         [0045]    (2) 50 ml of methylene chloride was added into the pale yellow clear viscous liquid obtained in step (1), and stirred for 30 min; then 540 ml of anhydrous ice diethyl ether was added, and stirred for 30 min; standing was performed for 12 h under 0° C., vacuum drying was performed after suction filtration, and refining was performed for three times according to the foregoing operation process to obtain the methoxypolyethylene glycol-polylactic acid block copolymer, wherein the total yield was about 70%. 
       Embodiment 8: Preparation of Methoxypolyethylene Glycol-Polylactic Acid Block Copolymer 
       [0046]    (1) 42.17 g of D,L-lactide and 57.89 g of methoxypolyethylene glycol 2000 were weighed for standby application, the methoxypolyethylene glycol 2000 was subjected to vacuum drying for 8 h under 100° C., nitrogen displacement was performed, D,L-lactide was added, and then 0.45 g of catalyst stannous octoate was added, evacuation was performed to a vacuum degree of 0.095 Mpa, a reaction temperature was maintained at 100° C., after the D,L-lactide was completely fused, evacuation was performed, the reactor was ensured to have a negative pressure and was sealed, the temperature was controlled to be raised to 130° C., and reaction was performed for 10 h, thus obtaining a pale yellow clear viscous liquid after the reaction was completed. 
         [0047]    (2) 75 ml of methylene chloride was added into the pale yellow clear viscous liquid obtained in step (1) for dissolution, and stirred for 30 min; then 720 ml of anhydrous ice diethyl ether was added, and stirred for 30 min; standing was performed for 12 h under 0° C., vacuum drying was performed after suction filtration, and refining was performed for three times according to the foregoing operation process to obtain the methoxypolyethylene glycol-polylactic acid block copolymer, wherein the total yield was about 80%. 
       Embodiment 9: Preparation of Methoxypolyethylene Glycol-Polylactic Acid Block Copolymer 
       [0048]    (1) 37.53 g of D,L-lactide and 62.71 g of methoxypolyethylene glycol 2000 were weighed for standby application, the methoxypolyethylene glycol 2000 was subjected to vacuum drying for 6 h under 110° C., nitrogen displacement was performed, then D,L-lactide was added, and 0.1 g of catalyst stannous octoate was added, evacuation was performed to a vacuum degree of 0.085 Mpa, a reaction temperature was maintained at 110° C., after the D,L-lactide was completely fused, evacuation was performed, the reactor was ensured to have a negative pressure and was sealed, the temperature was controlled to be raised to 140° C., and reaction was performed for 6 h, thus obtaining a pale yellow clear viscous liquid after the reaction was completed. 
         [0049]    (2) 40 ml of methylene chloride was added into the pale yellow clear viscous liquid obtained in step (1), and stirred for 30 min; then 556 ml of anhydrous ice diethyl ether was added, and stirred for 30 min; standing was performed for 12 h under 0° C., vacuum drying was performed after suction filtration, and refining was performed for three times according to the foregoing operation process to obtain the methoxypolyethylene glycol-polylactic acid block copolymer, wherein the total yield was about 80%. 
       Embodiment 10: Preparation of Methoxypolyethylene Glycol-Polylactic Acid Block Copolymer 
       [0050]    (1) 35.54 g of D,L-lactide and 64.68 g of methoxypolyethylene glycol 2000 were weighed for standby application, the methoxypolyethylene glycol 2000 was subjected to vacuum drying for 7 h under 100° C., nitrogen displacement was performed, D,L-lactide was added, and then 0.08 g of catalyst stannous octoate was added, evacuation was performed to a vacuum degree of 0.098 Mpa, nitrogen displacement was performed, and a reaction temperature was maintained at 100° C., after the D,L-lactide was completely fused, evacuation was performed, and nitrogen protection is performed, the temperature was controlled to be raised to 140° C., and reaction was performed for 12 h, thus obtaining a pale yellow clear viscous liquid after the reaction was completed. 
         [0051]    (2) 35 ml of methylene chloride was added into the pale yellow clear viscous liquid obtained in step (1) for dissolution, and stirred for 30 min; then anhydrous ice diethyl ether was added according to a ratio of 5 to 1 between the volume of the anhydrous ice diethyl ether and the weight of the pale yellow clear viscous liquid (i.e., ml/g) for extraction, and stirred for 30 min; standing was performed for 12 h under 0° C., vacuum drying was performed after suction filtration, and refining was performed for three times according to the foregoing operation process to obtain the methoxypolyethylene glycol-polylactic acid block copolymer, wherein the total yield was about 85%. 
       Embodiment 11: Preparation of Docetaxel Nano-Polymer Micelle Lyophilized Preparation 
       [0052]    (1) 20 g of docetaxel, 400 g (mPEG2000: PLA=1:0.99) of methoxypolyethylene glycol-polylactic acid block copolymer prepared in embodiment 1, 4000 ml of water, and 400 ml of organic solvent acetonitrile were taken for standby application. 
         [0053]    (2) 1000 ml of acetonitrile was added into standby docetaxel for ultrasound dissolution; then 400 g of methoxypolyethylene glycol-polylactic acid block copolymer was added for continuous dissolution, and then aseptic filtration was performed; then rotary evaporation was performed for 2 h under 50° C. and a rotation velocity of 80 r/min to boil off acetonitrile and obtain a docetaxel polymer gel film, 4000 g of 50° C. water was added quickly for vortex hydration, the temperature of the micelle solution was quickly reduced to 5° C. after complete hydration to obtain the micelle solution, then the micelle solution was subjected to aseptic filtration, sub-packaged and lyophilized. 
       Embodiments 12˜40: Preparation of Docetaxel Nano-Polymer Micelle Lyophilized Preparation 
       [0054]    The docetaxel nano-polymer micelle lyophilized preparation was prepared with reference to the preparation method in embodiment 11 and according to the dosage in Table 1, wherein a rotation velocity was controlled between 10 and 150 rpm, a temperature was between 20 and 28° C., and the time was 1˜4 h. 
         [0000]    
       
         
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
             
           
               
                 TABLE 1 
               
               
                   
               
               
                   
                   
                   
                   
                   
                 Dosage of 
                 Water 
               
               
                   
                 mPEG 2000 / 
                 mPEG 2000 - 
                   
                 Organic 
                 organic solvent 
                 dosage 
               
               
                 Item 
                 PLA 
                 PLA (g) 
                 DTX (g) 
                 solvent 
                 (ml) 
                 (ml) 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 Embodiment 
                 1:0.99 
                 400 
                 4 
                 Acetonitrile 
                 400 
                 4000 
               
               
                 11 
               
               
                 Embodiment 
                   
                 400 
                 36 
                   
                 600 
                 5000 
               
               
                 12 
               
               
                 Embodiment 
                   
                 400 
                 60 
                   
                 800 
                 6000 
               
               
                 13 
               
               
                 Embodiment 
                 1:0.95 
                 400 
                 8 
                 Acetone 
                 400 
                 4000 
               
               
                 14 
               
               
                 Embodiment 
                   
                 400 
                 30 
                   
                 600 
                 5000 
               
               
                 15 
               
               
                 Embodiment 
                   
                 400 
                 40 
                   
                 800 
                 6000 
               
               
                 16 
               
               
                 Embodiment 
                 1:0.91 
                 400 
                 6 
                 Ethyl 
                 400 
                 4000 
               
               
                 17 
                   
                   
                   
                 acetate 
               
               
                 Embodiment 
                   
                 400 
                 40 
                   
                 600 
                 5000 
               
               
                 18 
               
               
                 Embodiment 
                   
                 400 
                 50 
                   
                 800 
                 6000 
               
               
                 19 
               
               
                 Embodiment 
                 1:0.89 
                 400 
                 4 
                 Methylene 
                 400 
                 4000 
               
               
                 20 
                   
                   
                   
                 chloride 
               
               
                 Embodiment 
                   
                 400 
                 12 
                   
                 600 
                 5000 
               
               
                 21 
               
               
                 Embodiment 
                   
                 400 
                 36 
                   
                 800 
                 6000 
               
               
                 22 
               
               
                 Embodiment 
                 1:0.85 
                 400 
                 8 
                 Dimethyl- 
                 400 
                 4000 
               
               
                 23 
                   
                   
                   
                 formamide 
               
               
                 Embodiment 
                   
                 400 
                 36 
                   
                 600 
                 5000 
               
               
                 24 
               
               
                 Embodiment 
                   
                 400 
                 40 
                   
                 800 
                 6000 
               
               
                 25 
               
               
                 Embodiment 
                 1:0.80 
                 400 
                 6 
                 Dimethyl 
                 400 
                 4000 
               
               
                 26 
                   
                   
                   
                 sulfoxide 
               
               
                 Embodiment 
                   
                 400 
                 40 
                   
                 600 
                 5000 
               
               
                 27 
               
               
                 Embodiment 
                   
                 400 
                 50 
                   
                 800 
                 6000 
               
               
                 28 
               
               
                 Embodiment 
                 1:0.73 
                 400 
                 8 
                 Tetrahydro- 
                 400 
                 4000 
               
               
                 29 
                   
                   
                   
                 furan 
               
               
                 Embodiment 
                   
                 400 
                 45 
                   
                 600 
                 5000 
               
               
                 30 
               
               
                 Embodiment 
                   
                 400 
                 55 
                   
                 800 
                 6000 
               
               
                 31 
               
               
                 Embodiment 
                 1:0.65 
                 400 
                 6 
                 Methanol 
                 400 
                 4000 
               
               
                 32 
               
               
                 Embodiment 
                   
                 400 
                 36 
                   
                 600 
                 5000 
               
               
                 33 
               
               
                 Embodiment 
                   
                 400 
                 60 
                   
                 800 
                 6000 
               
               
                 34 
               
               
                 Embodiment 
                 1:0.60 
                 400 
                 8 
                 Short chain 
                 400 
                 4000 
               
               
                 35 
                   
                   
                   
                 fatty alcohol 
               
               
                 Embodiment 
                   
                 400 
                 40 
                   
                 600 
                 5000 
               
               
                 36 
               
               
                 Embodiment 
                   
                 400 
                 55 
                   
                 800 
                 6000 
               
               
                 37 
               
               
                 Embodiment 
                 1:0.55 
                 400 
                 4 
                 Short chain 
                 400 
                 4000 
               
               
                 38 
                   
                   
                   
                 fatty alcohol 
               
               
                 Embodiment 
                   
                 400 
                 36 
                   
                 600 
                 5000 
               
               
                 39 
               
               
                 Embodiment 
                   
                 400 
                 40 
                   
                 800 
                 6000 
               
               
                 40 
               
               
                   
               
             
          
         
       
     
       Embodiments 41: Characterization of Docetaxel Nano-Polymer Micelle Lyophilized Preparation 
       [0055]    (1)  FIG. 3  is a CDCl 3    1 HNMRprofile of the docetaxel nano-polymer micelle lyophilized preparation prepared in embodiment 11,  FIG. 4  is a D 2 O  1 HNMR profile of the docetaxel polymer micelle lyophilized preparation prepared in embodiment 11, and  FIG. 5  is a CDCl 3    1 HNMR profile of the methoxypolyethylene glycol polylactic acid block copolymer prepared in embodiment 1. Results show that the docetaxel was encapsulated in the core of the micelle, and a characteristic absorption peak of the docetaxel in the  1 HNMR profile of the micelle was not found. 
         [0056]    (2) A small quantity of the docetaxel nano-polymer micelle lyophilized preparation prepared in embodiment 11, docetaxel and the methoxypolyethylene glycol polylactic acid prepared in embodiment 1 were taken to perform Fourier transform infrared spectrum scanning, wherein results as shown in  FIG. 6 ,  FIG. 7  and  FIG. 8  proved that the docetaxel was encapsulated in the core of the micelle, and a characteristic absorption peak of the docetaxel in the profile of the micelle was not found. 
         [0057]    (3) A small quantity of the docetaxel nano-polymer micelle lyophilized preparation prepared in embodiment 11, docetaxel and the methoxypolyethylene glycol polylactic acid prepared in embodiment 1 were taken to perform thermal analysis scanning, wherein results as shown in  FIG. 9 ,  FIG. 10  and  FIG. 11  proved that the docetaxel was encapsulated in the core of the micelle, and a characteristic absorption peak of the docetaxel in the thermal-scanning profile of the micelle was not found. 
       Embodiment 42: Encapsulation Efficiency Detection Results of Docetaxel Nano-Polymer Micelle Lyophilized Preparation in Different Time After Re-Dissolving 
       [0058]    A control drug was prepared according to a recipe 17 (a ratio of polyethylene glycol to polylactic acid is 1:1.2, and a drug-carrying capacity is 6%) in embodiment 1 disclosed in CN201110105540.2. The docetaxel nano-polymer micelle lyophilized preparation was prepared according to the embodiment 11 of the present invention, which was an experimental group, wherein three parallel experiments were performed for the experimental group, and were marked as embodiment 11-1, embodiment 11-2 and embodiment 11-3. Physiological saline was added into the preparation of the control group and the experimental group respectively for dissolution until the concentration was lmg/ml (by docetaxel), and then placed under a room temperature (25±2° C.) to detect the encapsulation efficiency thereof in different time. Results were as shown in Table 2. 
         [0059]    The encapsulation efficiency of the micelle was measured using high speed centrifugation (10000 r/min, 10min), wherein the encapsulation efficiency=(1−free drug/total drug)*100%. When determining the encapsulation efficiency of the docetaxel polymer micelle using HPLC, chromatogram conditions used were as follows: ODS was used as a filling material, 0.043 mol/L ammonium acetate aqueous solution-acetonitrile (45:55) was used as a mobile phase, and a detection wavelength was 230 nm. Theoretical plate number calculated by a docetaxel peak should not be less than 2000. 
         [0000]    
       
         
               
             
               
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 2 
               
             
             
               
                   
               
               
                 Encapsulation efficiency detection results of docetaxel nano-polymer 
               
               
                 micelle lyophilized preparation in different time after re-dissolving 
               
             
          
           
               
                 Time (Hour) 
                 0 
                 0.5 
                 1 
                 2 
                 5 
                 8 
                 12 
                 15 
               
               
                   
               
               
                 Control group 
                 96.7% 
                     55% 
                 45.2% 
                 33.7% 
                 27.6% 
                 15.1% 
                 10.2% 
                  8.5% 
               
               
                 Embodiment 
                 98.3% 
                     98% 
                     98% 
                 97.4% 
                 97.3% 
                 96.9% 
                 90.3% 
                 81.2% 
               
               
                 11-1 
               
               
                 Embodiment 
                 97.3% 
                 97.0% 
                 96.4% 
                 96.0% 
                 95.6% 
                 93.1% 
                 90.4% 
                 78.5% 
               
               
                 11-2 
               
               
                 Embodiment 
                 98.1% 
                 97.5% 
                 95.6% 
                 95.1% 
                 94.4% 
                 92.8% 
                 90.1% 
                 76.8% 
               
               
                 11-3 
               
               
                   
               
             
          
         
       
     
         [0060]    As shown in Table 2, the encapsulation efficiency of the drug in the experimental group was still greater than 90% at 12 h, while burst release occurred to the drug in the control group at 0.5 h.